Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms REMARC
- 20 Apr 2017 Results published in the Journal of Clinical Oncology.
- 06 Dec 2016 First analysis results of the REMARC study, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 28 Oct 2016 Data from this trial will be presented at the 2016 American Society of Hematology (ASH) annual meeting, as reported by a Celgene Corporation media release.